翰森製藥(03692.HK)簽訂藥品於中國的獨家商業權益
翰森製藥(03692.HK)公佈,全資附屬翰森(上海)健康科技及江蘇豪森藥業集團已與OliX Pharmaceuticals訂立獨家許可合作協議,OliX Pharmaceuticals將利用GalNAc-asiRNA平臺技術,以發現先導藥物,並確保針對與肝臟相關的心血管、代謝及其他疾病的靶點的候選藥物開發。
翰森將擁有相關療法於中國及港澳地區的獨家商業權益,OliX Pharmaceuticals將擁有該地域以外其他地區的權益,並將收到650萬美元的首付款,以及基於重要裏程碑最高爲4.5億美元的款額與特許權許可分成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.